Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial)
BMJ Open October 1, 2022 Mathias Ebbesen Jensen, Dea Siggaard Stenbæk, Tobias Søgaard Juul et al. 21 citations
A planned clinical trial will test whether psilocybin-assisted therapy, compared to a placebo, reduces heavy drinking in people with alcohol use disorder. Ninety treatment-seeking adults aged 20–70 will be randomly assigned to receive either psilocybin or placebo alongside psychological support. The main outcome is the change in percentage of heavy drinking days from baseline to 12 weeks after dosing. Secondary outcomes include total alcohol consumption, a blood biomarker for alcohol, the active drug metabolite in blood, the subjective drug experience, and brain responses to alcohol cues measured with functional MRI one week after dosing. The trial is registered and has ethical approval.